CASMU Polyclinic 8 de Octubre 3310 Montevideo, Uruguay Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2017
NCT03016949
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

f-ipv (1 trial)

ipv (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Poliomyelitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2